What did @bpaigea actually say?
She said estrogen patch instability, not dose size, is what causes bloating and mood swings for her. She uses a 0.05mg patch, 200mg micronized progesterone taken vaginally for the last 12-14 days of her cycle, and 5mg compounded testosterone cream after bad experiences with standard pharmacy testosterone products. Her central argument: "when you have the peaks and the troughs, that's when you feel crazy." She also claims vaginal progesterone is "twice as effective" compared to oral.
She is describing a real phenomenon in HRT management. Transdermal patch pharmacokinetics vary by formulation, body site, sweating, heat exposure, and activity. These are not imaginary factors. She is also not pretending to give medical advice universally, she repeatedly says to talk to your doctor. Credit where it's due.
Does the science back this up?
Mostly, yes, with one significant caveat on the progesterone claim. The patch stability issue is well-documented. The vaginal progesterone claim needs more precision than she gives it.
On patch variability: a 2015 study by Järvinen et al. in Maturitas confirmed that physical activity, heat, and skin site significantly affect transdermal estradiol absorption rates. Women who exercise heavily or use saunas can absorb estradiol faster, shortening effective duration and creating exactly the peaks and troughs she describes. This is pharmacokinetics, not opinion.
On vaginal progesterone bioavailability: the "twice as effective" claim is a loose version of a real finding. Research by Cicinelli et al. (1996, Fertility and Sterility) described a "first uterine pass effect" where vaginally administered progesterone achieves higher endometrial concentrations at lower systemic doses compared to oral. But "twice as effective" systemically is an oversimplification. For women sensitive to progesterone side effects like sedation, vaginal delivery genuinely reduces systemic exposure while maintaining uterine protection. The mechanism is real. The phrasing is imprecise.
What did they get wrong, or right?
She got the patch instability argument right. She got the direction of the vaginal progesterone claim right but overstated the magnitude. The testosterone section is where things get complicated.
She reports hair shedding, unwanted hair growth, and mood symptoms with standard pharmacy testosterone and attributes this to it being "the men's product." That explanation is not scientifically supported. Compounded testosterone creams and FDA-approved gels contain the same active molecule, testosterone. Any differences in her response are almost certainly about dose and absorption rate, not the product category. A 1% testosterone gel dosed for men delivers far more testosterone than a 5mg women's compounded cream. The comparison is essentially a dose comparison, not a formulation category comparison. Framing it as men's product versus women's product is misleading and could push viewers toward compounding without understanding why the dose difference is the actual variable.
Her testosterone level of 31 ng/dL on 4mg cream is within the range some guidelines consider low-normal for premenopausal women, though reference ranges for women on exogenous testosterone are not well standardized (Davis et al., 2019, Lancet Diabetes and Endocrinology).
What should you actually know?
If you are on an estrogen patch and feeling unstable, patch brand and formulation actually matter. Generic patches are not always bioequivalent in practice even when regulators say they are. A 2020 paper by Shulman et al. in Menopause documented real-world variability in patient response when switching between brand and generic transdermal estradiol. Ask your prescriber specifically about formulation, not just dose.
Vaginal progesterone is a legitimate clinical option, particularly for women who experience sedation or mood effects from oral micronized progesterone. The data supporting uterine protection via vaginal delivery is solid. The data on whether it reduces side effects for every sensitive patient is less conclusive. It is an option, not a universal upgrade.
On testosterone: women's doses are genuinely tiny compared to men's doses. The difference between 5mg and 100mg is not a rounding error. If you had a bad experience with a pharmacy testosterone product, talk to your doctor about whether it was actually a dose issue before attributing it to the product category. Compounded preparations are not standardized and carry their own variability risks, which the FDA has noted repeatedly.
Bottom line on this video
This is a more informed patient experience video than most in the HRT space. The core claims about patch variability affecting symptoms and vaginal progesterone being a legitimate alternative are grounded in real pharmacology. The testosterone explanation oversimplifies in a way that could mislead viewers into thinking formulation category matters more than dose. Watch it as a starting point for questions to ask your own provider, not as a protocol to replicate.